Last updated: October 4, 2026
MIOCHOL-E is a mature ophthalmic surgical drug containing acetylcholine chloride. Bausch + Lomb markets the product in the United States for rapid, short-duration miosis during anterior-segment surgery. Its commercial profile is defined by low unit volume, procedure-linked demand, hospital purchasing, limited clinical substitution, and supply-chain sensitivity rather than prescription-market growth.
Standalone revenue, gross margin, and unit sales for MIOCHOL-E are not publicly disclosed. Bausch + Lomb reports the product within broader pharmaceutical and ophthalmic portfolios, preventing a product-level financial reconstruction. The most defensible financial conclusion is that MIOCHOL-E is a small, established cash-generating product with modest growth potential and limited patent-driven protection.
What is MIOCHOL-E and how is it used?
MIOCHOL-E is an intraocular formulation of acetylcholine chloride supplied as a sterile, lyophilized powder with a diluent. After reconstitution, surgeons inject it into the anterior chamber to produce rapid miosis during cataract surgery and other anterior-segment procedures.
The product is used in procedures where controlled pupil constriction is clinically useful after lens implantation or other intraocular manipulation. Its effect is short-lived, which fits the operating-room setting but limits use outside surgery.
| Attribute |
MIOCHOL-E profile |
| Active ingredient |
Acetylcholine chloride |
| Dosage form |
Sterile intraocular solution after reconstitution |
| Primary use |
Induction of miosis during ophthalmic surgery |
| Administration |
Intraocular, administered by ophthalmic surgeons |
| Market channel |
Hospitals, ambulatory surgery centers, specialty distributors |
| U.S. sponsor/marketer |
Bausch + Lomb |
| FDA regulatory pathway |
Legacy prescription drug product approved under an NDA |
| Revenue disclosure |
No standalone public disclosure |
| Main commercial drivers |
Cataract and anterior-segment procedure volume, supply reliability, formulary status |
The U.S. prescribing information identifies hypersensitivity, corneal edema, inflammation, and other ocular complications as relevant risks. MIOCHOL-E is administered by trained surgical personnel, so demand is tied to operating-room protocols rather than direct patient prescribing.[1]
What is the FDA regulatory status of MIOCHOL-E?
MIOCHOL-E is an FDA-approved prescription ophthalmic drug. The product is associated with legacy NDA 018919 in FDA drug databases and has been marketed for decades.[2]
Its regulatory position is stronger than that of an unapproved compounded intraocular preparation because the commercial product has established manufacturing, labeling, sterility controls, and surgical-use history. That regulatory status supports continued hospital purchasing even when lower-cost compounded or alternative products are available.
Does MIOCHOL-E have FDA exclusivity?
No meaningful period of modern FDA regulatory exclusivity protects MIOCHOL-E. Any new-drug exclusivity associated with its original approval expired long ago. The product is a mature small-molecule drug, and its competitive position depends on manufacturing quality, supply continuity, surgeon familiarity, and account-level contracting.
The key distinction is between regulatory approval and commercial exclusivity:
- FDA approval supports lawful marketing under the approved label.
- FDA exclusivity is time-limited and does not remain active for a legacy product of this age.
- Brand recognition and hospital qualification can persist after exclusivity expires.
- Sterile manufacturing requirements can create practical barriers even when patent protection is absent.
What patents protect MIOCHOL-E?
No active, commercially significant patent estate is publicly associated with the core MIOCHOL-E product. Acetylcholine chloride is an old active pharmaceutical ingredient, and the product’s principal commercial protection does not appear to come from composition-of-matter patents.
Potentially relevant rights would involve formulation, packaging, sterile manufacturing, or use-specific claims. Those rights would need to be current, enforceable, and listed or asserted against a competing product to create material exclusivity. Public FDA and patent records do not indicate that MIOCHOL-E has a modern patent position comparable to newer ophthalmic delivery systems.[2,3]
| Protection category |
MIOCHOL-E position |
| Active-ingredient patent |
Expired or not commercially relevant |
| New chemical entity exclusivity |
Expired |
| Formulation patent |
No material active estate publicly evident |
| Device or delivery patent |
Not central to the marketed product |
| Method-of-use patent |
No material current exclusivity publicly evident |
| Trade-secret protection |
Possible for manufacturing controls, but not publicly quantifiable |
| Orange Book value |
Limited absent active listed patents |
Is MIOCHOL-E listed in the Orange Book?
MIOCHOL-E is associated with an FDA-approved NDA, but its commercial defense does not appear to depend on a current Orange Book patent listing. An Orange Book listing would matter mainly if a generic applicant filed an abbreviated new drug application with a Paragraph IV certification against an unexpired patent.
The practical risk is therefore not patent litigation. It is the entry of an approved or compounded competitor that can satisfy sterile intraocular manufacturing, hospital qualification, and distribution requirements.
When does MIOCHOL-E lose exclusivity?
MIOCHOL-E lost meaningful statutory exclusivity decades ago. The product is already in the post-exclusivity phase.
The relevant timeline is:
| Period |
Commercial or regulatory event |
| Legacy approval period |
Acetylcholine chloride intraocular product approved under an FDA NDA |
| Post-approval decades |
Product established in ophthalmic operating rooms |
| Patent and exclusivity expiry |
Core protection expired long before the current commercial period |
| Current market |
Mature branded product competing through supply, quality, and procurement |
| Future outlook |
Continued sales depend on procedure volumes and manufacturing reliability |
The absence of active exclusivity does not automatically produce rapid generic erosion. Sterile ophthalmic products have higher manufacturing and quality requirements than conventional oral tablets. A competitor must produce a consistent, sterile, intraocular formulation and secure hospital adoption.
How large is the MIOCHOL-E market?
MIOCHOL-E addresses a narrow institutional market. Its demand is linked primarily to cataract surgery and other anterior-segment procedures, not to the total population with ophthalmic disease.
Cataract surgery is the principal volume driver. The global cataract-surgery market is large and generally expanding because of aging populations, rising surgical access, and increased procedure capacity. MIOCHOL-E captures only a small portion of the value created by those procedures because it is one low-cost surgical input among numerous pharmaceuticals, implants, instruments, and operating-room supplies.[4]
What factors drive demand?
Demand is influenced by:
- Cataract and anterior-segment procedure volume.
- The number of hospitals and ambulatory surgery centers using intraocular miotics.
- Surgeon preference and operating-room protocols.
- Availability of alternatives, including carbachol products and compounded preparations.
- Distributor inventory and wholesaler purchasing patterns.
- Product wastage caused by single-use packaging and procedure scheduling.
- Hospital pharmacy and group-purchasing contracts.
MIOCHOL-E does not benefit materially from consumer advertising or chronic refill behavior. A procedure slowdown can reduce demand quickly, while a supply disruption can shift purchases to alternatives.
How does MIOCHOL-E compare with competing ophthalmic miotics?
The main competitive set includes carbachol-based products, compounded intraocular miotics, and surgical techniques that reduce the need for a separate miotic in selected cases.
| Product or alternative |
Active ingredient or approach |
Competitive advantage |
Limitation |
| MIOCHOL-E |
Acetylcholine chloride |
Established brand, familiar surgical use, FDA-approved product |
Reconstitution, short duration, mature product economics |
| Miostat-type products |
Carbachol |
Longer-acting cholinergic effect in some surgical settings |
Availability and market access vary |
| Compounded intraocular miotics |
Variable |
Potentially lower price or local availability |
Quality, sterility, and regulatory oversight vary |
| Pharmacologic alternatives |
Other intraocular agents |
May support different surgical protocols |
Not always directly interchangeable |
| Mechanical or procedural techniques |
Surgical approach |
Can reduce dependence on a separate miotic |
Requires surgeon-specific technique and equipment |
MIOCHOL-E’s strongest competitive advantage is reliability within a familiar surgical workflow. Its weakness is the absence of durable intellectual-property protection and the limited switching cost for institutions that qualify another sterile product.
What is the financial trajectory of MIOCHOL-E?
MIOCHOL-E is likely a stable-to-low-growth product at the brand level, with episodic revenue volatility caused by supply, contracting, and procedure trends. Public filings do not disclose product-level sales, so no defensible standalone revenue series or compound annual growth rate can be calculated.
Revenue profile
The product’s financial characteristics are likely to include:
- Low annual unit volume relative to oral or chronic ophthalmic medicines.
- Moderate revenue per vial relative to manufacturing cost, depending on institutional pricing.
- High sensitivity to wholesaler and hospital contracts.
- Limited promotional spending.
- Stronger margins than a commodity sterile product if brand supply is reliable.
- Downward price pressure when an approved generic or compounded alternative is available.
- Inventory-driven quarterly volatility.
Bausch + Lomb’s public reporting aggregates products across eye care, surgical, consumer, and pharmaceutical categories. MIOCHOL-E is not reported as an independent revenue line. The product therefore cannot be valued from public filings using a conventional brand-level revenue forecast.[5]
Scenario-based financial outlook
| Scenario |
Market condition |
Revenue effect |
Margin effect |
| Base case |
Stable cataract volumes and continued brand purchasing |
Flat to low-single-digit growth |
Stable, with procurement pressure |
| Upside case |
Procedure growth, competitor disruption, improved supply |
Moderate temporary growth |
Potentially favorable |
| Downside case |
Approved generic entry, sustained shortages, or formulary replacement |
Material decline |
Margin compression |
| Severe downside |
Loss of reliable supply or broad substitution |
Rapid volume loss |
Fixed-cost absorption pressure |
The most likely trajectory is maturity rather than rapid expansion. Growth in cataract procedures can offset some erosion, but it is unlikely to create a large revenue inflection for a single legacy surgical product.
What generic entry risks exist for MIOCHOL-E?
Generic entry is possible in principle but operationally more difficult than entry for a standard oral drug. A competing applicant would need to address:
- Sterile manufacturing and aseptic processing.
- Reconstitution stability.
- Container-closure integrity.
- Particulate and endotoxin controls.
- Intraocular safety.
- Labeling and administration instructions.
- Distribution to hospitals and surgery centers.
- Product availability during procedure scheduling.
A generic competitor could pressure MIOCHOL-E through lower contract pricing even without capturing the entire market. Hospital systems often retain multiple qualified suppliers for shortage management and purchasing leverage.
The risk is asymmetric. A single competitor may produce a meaningful price decline without eliminating the brand. A broader supply disruption affecting the brand could produce temporary share gains for alternatives, but those gains may reverse after supply normalizes.
Which companies are challenging MIOCHOL-E?
No major patent challenge or high-profile Paragraph IV litigation is publicly associated with MIOCHOL-E. The competitive threat is more likely to come from manufacturers of sterile ophthalmic products, regional suppliers, compounding pharmacies, and sellers of alternative intraocular miotics than from a patent-litigation campaign.
The relevant competitive groups are:
- Generic ophthalmic manufacturers.
- Contract manufacturers with sterile injectable capacity.
- Specialty ophthalmic companies.
- Hospital-compounding operations.
- Suppliers of carbachol or other intraocular surgical drugs.
The absence of prominent litigation indicates that market entry barriers are primarily regulatory, technical, and commercial.
What manufacturing and intellectual-property barriers protect MIOCHOL-E?
Manufacturing capability is more important than patent rights. The product must meet the quality requirements applicable to an intraocular sterile product. Small defects in sterility, particulate control, concentration, or reconstitution performance can create serious clinical and regulatory consequences.
Manufacturing barriers include:
- Qualified sterile production lines.
- Validated aseptic processes.
- Reliable supply of pharmaceutical-grade acetylcholine chloride.
- Batch-release testing.
- Stable vial and diluent packaging.
- FDA inspection readiness.
- Hospital confidence in continuity of supply.
These barriers support a degree of practical protection, but they do not create permanent exclusivity. A well-capitalized generic manufacturer can overcome them.
What litigation and settlement agreements affect MIOCHOL-E?
No material public patent litigation or settlement agreement is identified as affecting MIOCHOL-E’s current commercial position. The product’s risk profile is therefore different from newer branded drugs with active Orange Book patents and Paragraph IV settlements.
Potential disputes would more likely involve:
- Product liability.
- Manufacturing compliance.
- Distribution or supply contracts.
- Compounding oversight.
- Trademark or labeling issues.
There is no apparent litigation-driven launch calendar for MIOCHOL-E.
What is the biosimilar risk for MIOCHOL-E?
Biosimilar risk is not relevant. MIOCHOL-E is a small-molecule drug, not a biologic. Any competitive product would proceed through a generic or other small-molecule regulatory pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.
What licensing deals affect MIOCHOL-E?
No major recent licensing transaction centered on MIOCHOL-E is publicly disclosed. The product is marketed within Bausch + Lomb’s broader ophthalmic business rather than through a widely reported external licensing structure.
Potential commercial arrangements may include distributor, group-purchasing, and hospital supply contracts. Those agreements are typically not disclosed publicly and cannot be treated as evidence of a separate licensing-based revenue stream.
What is the geographic coverage of MIOCHOL-E?
MIOCHOL-E has its strongest commercial relevance in the United States, where Bausch + Lomb maintains an established ophthalmic presence and the product has FDA approval. Availability and branding may differ by country because local registrations, distributors, and competing formulations vary.
Geographic performance depends on:
- National approval status.
- Local hospital procurement.
- Cataract-surgery volumes.
- Reimbursement and procedure economics.
- Availability of carbachol and compounded alternatives.
- Local sterile-manufacturing capacity.
The United States is likely the most commercially visible market, but international sales cannot be estimated reliably from public disclosures.
How strong is the MIOCHOL-E commercial position?
MIOCHOL-E has a moderate commercial position and a weak exclusivity position.
| Factor |
Assessment |
| Clinical need |
Moderate, concentrated in surgery |
| Brand recognition |
Established among ophthalmic surgeons |
| Patent strength |
Weak or immaterial |
| Regulatory position |
Strong relative to unapproved alternatives |
| Switching costs |
Moderate at the account and workflow level |
| Generic vulnerability |
Moderate |
| Supply-chain sensitivity |
High |
| Growth potential |
Low to moderate |
| Financial transparency |
Low |
| Litigation risk |
Low based on public record |
The product can remain commercially durable without patent protection because hospitals value dependable sterile supply and familiar surgical products. Its long-term weakness is that a credible competitor can attack price and share without needing to overcome a strong patent barrier.
Key Takeaways
- MIOCHOL-E is a mature acetylcholine chloride product used to induce miosis during ophthalmic surgery.
- Bausch + Lomb markets the product, but standalone sales and profitability are not publicly disclosed.
- The product has no apparent active patent estate that creates meaningful market exclusivity.
- FDA exclusivity expired long ago; the current defense is approval status, manufacturing quality, surgeon familiarity, and supply reliability.
- Demand is tied mainly to cataract and anterior-segment procedure volumes.
- Generic and compounded alternatives create moderate long-term erosion risk.
- Biosimilar competition does not apply because MIOCHOL-E is a small-molecule drug.
- No material Paragraph IV challenge, patent litigation, or settlement agreement is publicly associated with the product.
- The most likely financial trajectory is stable to low growth, with volatility from supply disruptions and hospital contracting.
- Manufacturing and sterile-quality requirements are the principal barriers to entry.
FAQs
Is MIOCHOL-E still commercially available?
MIOCHOL-E remains an FDA-approved ophthalmic surgical product marketed by Bausch + Lomb, although product availability can vary by distributor, hospital account, and supply conditions.
Is acetylcholine chloride the same as carbachol?
No. Both are cholinergic miotics used in ophthalmic surgery, but acetylcholine chloride and carbachol are different active ingredients with different pharmacologic and formulation profiles.
Can a pharmacy compound a substitute for MIOCHOL-E?
Compounding may provide an alternative in some settings, but compounded products can differ in regulatory status, sterility controls, availability, and institutional acceptance. They are not automatically interchangeable with an FDA-approved product.
Does MIOCHOL-E have generic competition?
The product is vulnerable to generic or alternative sterile ophthalmic competition, but the existence and commercial scale of a direct FDA-approved generic must be verified through current FDA product listings and market-availability data.
Is MIOCHOL-E a high-growth pharmaceutical asset?
No. MIOCHOL-E is best characterized as a mature, niche surgical pharmaceutical asset. Its value lies in recurring procedure-linked demand and established market access, not in rapid volume growth or patent-protected pricing.
References
-
Bausch + Lomb Incorporated. (2023). Miochol-E: Acetylcholine chloride intraocular solution prescribing information. U.S. Food and Drug Administration labeling database.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, NDA 018919. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. https://ppubs.uspto.gov/
-
American Academy of Ophthalmology. (2023). Cataract in the adult eye preferred practice pattern. https://www.aao.org/education/preferred-practice-pattern
-
Bausch + Lomb Corporation. (2024). Annual report and securities filings. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=0001860742
